BARCELONA, Spain — September 15, 2022- Veeva Systems (NYSE: VEEV) today announced Batavia Biosciences selected Veeva Vault Quality Suite to optimize its global quality assurance (QA), unifying content, processes, and training management on a single platform. Batavia will also benefit from real-time insights that support ongoing QA improvements and inspection readiness.
“As our development footprint grew globally, we needed to optimize our QA approach to better meet future needs,” said Jolanda Van Vliet, director of quality assurance, Batavia Biosciences. “Bringing our QA onto Veeva’s cloud-based platform enables us to centrally manage quality documentation and training, facilitate collaboration among authors, and improve reaction time to quality events.”
Based in the Netherlands, Batavia Biosciences is a full-service contract development and manufacturing organization (CDMO) specializing in viral vaccines, virotherapy, and protein vaccines. With Veeva Vault QMS, Batavia can centrally manage QA processes to better ensure GxP compliance, while Veeva Vault QualityDocs automates workflows and audit trails, simplifying document management, updates, and review processes. Veeva Vault Training will further help the CDMO ensure role-based qualifications.
“It is a privilege to partner with Batavia to support their launch of a fully digital quality assurance system and boost inspection readiness,” said Sofia Lange, director strategy, Vault Quality & Manufacturing at Veeva. “With the addition of Vault Quality Suite, Batavia now has a scalable foundation that will strengthen its QA processes and oversight across operations.”
Additional Information
For more on Veeva Vault Quality Suite, visit: veeva.com/VaultQuality
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
